MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2022 International Congress

    Patient and caregiver satisfaction of video-assisted telenursing in patients treated with LCIG

    T. Gurevich, A. Evans, G. Kägi, D. Koziorowksi, L. Bergmann, JC. Parra Riaza, O. Sanchez-Soliño, J. Slawek (Tel Aviv, Israel)

    Objective: To evaluate the feasibility and patient satisfaction of video-assisted telenursing as well as demonstrate resolution for treatment-related issues in the real-word levodopa-carbidopa intestinal gel…
  • 2022 International Congress

    Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy

    M. Lin, R. Laureno, A. Lenka (Washington, USA)

    Objective: To evaluate the natural progression of Parkinson disease (PD) in patients on less pulsatile levodopa therapy (LPT). Background: Previously we have shown that patients…
  • 2022 International Congress

    Comparing duodenal levodopa infusion based on length of treatment in advanced Parkinson’s.

    J. Alonso Maroto, E. Casas Peña, I. Muro García, M. Domínguez Gallego, E. Valiente Gordillo, L. López Manzanares, JA. Vivancos Mora (Madrid, Spain)

    Objective: In this study we seek to compare characteristics and complications of patients suffering from advanced Parkinson's treated with duodenal levodopa infusion. Background: Motor fluctuations…
  • 2022 International Congress

    Heart rate variability is affected by standing and medication intake in Parkinson’s disease

    F. Cucinotta, F. Morgante, I. Cociasu, E. Pereira, E. Makovac, L. Ricciardi (London, United Kingdom)

    Objective: To evaluate the effect of levodopa and orthostatism on heart rate variability (HRV) in a sample of consecutive subjects with Parkinson's disease (PD). Background:…
  • 2022 International Congress

    Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias

    A. Simonyan, V. Tyurnikov, V. Poleshuk, A. Simonyan, A. Gushcha (Moscow, Russian Federation)

    Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…
  • 2022 International Congress

    Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)

    D. Grosset, P. Zhao, R. Marini, R. Cohen, B. Blank (Glasgow, United Kingdom)

    Objective: An analysis of the proportion of patients who turned ON after levodopa inhalation powder (CVT-301) 84mg treatment vs placebo, compared across subgroups of patients…
  • 2022 International Congress

    The benefit of exclusive nocturnal administration of a levodopa-carbidopa intestinal infusion for severe refractory sleep behavior disorder in Parkinson’s disease

    M. Rivera Sánchez, A. Sánchez Rodríguez, M. Sierra, I. González-Aramburu, MV. Sánchez Peláez, M. Martínez, J. Infante (Santander, Spain)

    Objective: Treatment by continuous diurnal intestinal infusion of levodopa is effective in improving sleep quality in Parkinson's disease (PD), but its use exclusively at night…
  • 2022 International Congress

    Levodopa Carbidopa Intestinal Gel in Patients with Deep Brain Stimulation in Parkinson’s disease- First case series from Middle-East Region

    S. Mittal, A. Aldakheel, W. Mohammed, T. Alkhairallah, B. Klassen, M. Thomas, T. Maiti, S. Wasti (Abu Dhabi, United Arab Emirates)

    Objective: The objective is to report unique and challenging cases, who had successful control of Parkinson’s disease (PD) symptoms with combination therapy of Deep Brain…
  • 2022 International Congress

    Clinical and risk profiles of Parkinson’s disease from a large pan-India cohort: interim observations of the GAP-India study

    A. Kishore, R. Borgohain, R. Rajan, K. Divya, L. Prashanth, P. Pal, S. Mehta, H. Kumar, N. Kumar, S. Desai, R. Kamdadai, S. Krishnan, M. Chacko, M. Sharma (Kochi, India)

    Objective: To create a pan-Indian clinical repository of Parkinson’s Disease (PD). Background: The genetic risk for PD in India is unknown. The Luxembourg-German India Alliance…
  • 2022 International Congress

    OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?

    F. Colucci, V. Rispoli, V. Tugnoli, M. Pugliatti, G. Tecilla, M. Sensi (Ferrara, Italy)

    Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley